dasatinib

The drug is indicated for the treatment of adults with newly diagnosed chronic myeloid leukemia (CML) in chronic phase, as well as for patients with CML in accelerated phase or acute Ph+ lymphoblastic leukemia (ALL) in cases of resistance or intolerance to prior therapy. It is also used for the treatment of children with appropriate forms of leukemia.

Form: tablets, film-coated

ATC: L01EA02

Manufacturer: PLIVA Hrvatska d.o.o.

The drug is intended for the treatment of adults with chronic myeloid leukemia (CML) in chronic, accelerated, or blast phase, as well as acute Ph+ lymphoblastic leukemia (ALL). It is also used for the treatment of children with appropriate forms of these diseases.

Form: tablets, film-coated

ATC: L01EA02

Manufacturer: PLIVA Hrvatska d.o.o.

The drug is indicated for the treatment of adults with chronic myeloid leukemia (CML) with the Philadelphia chromosome (Ph+), as well as for patients with CML in accelerated phase or blast crisis, if previous imatinib treatment was ineffective or not tolerated. It is also used for the treatment of acute Ph-positive lymphoblastic leukemia (ALL). In children, the drug is prescribed for Ph+ CML in chronic phase or Ph+ ALL.

Form: tablets, film-coated

ATC: L01XE06

Manufacturer: Synthon Hispania, S.L. (manufacturing (full cycle))

The drug is indicated for the treatment of adults with chronic myeloid leukemia (CML) with the Philadelphia chromosome, as well as for patients with CML in accelerated phase or blast crisis who are resistant to imatinib. It is also used for the treatment of acute Ph-positive lymphoblastic leukemia (ALL). The drug is also indicated for children with appropriate forms of leukemia.

Form: tablets, film-coated

ATC: L01XE06

Manufacturer: Synthon Hispania, S.L. (manufacturing (full cycle))

The drug is indicated for the treatment of adults with chronic myeloid leukemia (CML) with the presence of the Philadelphia chromosome, as well as for patients with CML in accelerated phase or blast crisis who have resistance to previous treatment. It is also used for the treatment of acute Ph+ lymphoblastic leukemia (ALL). In children, the drug is prescribed for Ph+ CML in chronic phase or Ph+ ALL.

Form: tablets, film-coated

ATC: L01XE06

Manufacturer: Synthon Hispania, S.L. (manufacturing (full cycle))

The drug is indicated for the treatment of adults with chronic myeloid leukemia (CML) with the Philadelphia chromosome, as well as for patients with CML in accelerated phase or blast crisis who are resistant to imatinib. It is also used for the treatment of acute Ph+ lymphoblastic leukemia (ALL). In children, the drug is prescribed for Ph+ CML in chronic phase or Ph+ ALL.

Form: tablets, film-coated

ATC: L01XE06

Manufacturer: Synthon Hispania, S.L. (manufacturing (full cycle))